Seeking Alpha

The FDA votes 12 no to 2 yes on the risk/benefit of Depomed's (DEPO) Gabapentin in treating...

The FDA votes 12 no to 2 yes on the risk/benefit of Depomed's (DEPO) Gabapentin in treating moderate to severe vasomotor symtoms due to menopause, 13 no and 1 yes on its efficacy. Shares remain halted.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector